Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Cipla
Cipla
Activities:
Ingredients
Drug Delivery
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Cipla and Kemwell announce joint venture for biosimilars
The venture will leverage the companies’ combined strengths in product development, clinical development, regulatory filings, manufacturing and commercialisation
Ingredients
Cipla signs COVID-19 licensing agreement with Gilead Sciences
Indian Cipla will be permitted to manufacture US-based Gilead’s API and finished product of Remdesivir and market it in 127 countries including India and South Africa under its own brand name
Research & Development
Indian Cipla funnels $1 million into facility in Minsk
The facility will be used to localise the production of innovative solid medicines in Belarus
Finance
Cipla to step up efforts in US market
Competition heating up, with the US Food and Drug Association approving rival drugs, which could eat away at Cipla's market share in the generic business.
Regulatory
Indian pricing authority to address overcharging by pharma companies
NPPA has decided to chase drug majors for defaulting on penalties that have been imposed for overcharging consumers for medicines
Finance
Cipla to acquire two US generics companies for $550m
Acquisition of InvaGen gives Cipla scale in the US generics market with a strong manufacturing and R&D base, access to a broad product portfolio and a strong customer base
Regulatory
Boehringer Ingelheim suffers Spiriva patent blow in India
Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
Subscribe now